HemoCue AB, a global leader in IVD point-of-care testing, announces that it has entered into a Settlement Agreement with EKF Diagnostics Holdings plc (“EKF”) in relation to patent related litigation in Germany and the US.
As a result of the Settlement Agreement all claims are mutually settled and finally resolved.
The effect of this is that EKF´s original design cuvette can not be sold in the following countries: the United States, Germany, Great Britain, Sweden, Denmark, Finland, the Netherlands, Spain, Italy, Switzerland, Japan, South Africa and China. EKF can sell this original design cuvette in other countries.
The HemoCue family of companies, acquired by Quest Diagnostics in 2007, is a global leader in a field of diagnostics known as near patient, or point-of-care, testing. In 1982, HemoCue AB, based in Ängelholm, Sweden, introduced the first system making accurate Hemoglobin testing possible in near-patient settings. Since then, more than 350,000 HemoCue systems have been sold worldwide. The company also manufactures point-of-care tests for Glucose, Urine Albumin, Total and Differential White Blood Cell count. HemoCue subsidiaries, affiliates, franchises, and third-party distributors generate revenue in more than 130 countries world wide. Additional company information is available at www.hemocue.com.
# # #
Managing Director HemoCue
Tel: +46 431481326
Quest Diagnostics, Corporate Communications
Tel: +1 973-520 2045